Novartis' $3.1 Billion Pipeline Reintegration: A New Model for Pharma M&A?

Novartis’ recent $3.1 billion acquisition of Anthos Therapeutics is more than just a transaction—it’s a strategic pipeline reintegration move that could signal a new era in biopharma M&A. The deal brings abelacimab, a promising Factor XI inhibitor for stroke prevention, back under Novartis’ control after it was spun out to Anthos, a Blackstone-backed biotech, in 2019